Help Chart the Course in Kidney Health Research

Receive personalized treatment care for your
Lupus Nephritis (LN), IgA Nephropathy (IgAN), or
C3 Glomerulopathy (C3G), in the SPOTLIGHT Study

Conditions We're Supporting

This clinical study focuses on understanding and treating three conditions that can lead to serious kidney disease. Each of these conditions involves the immune system acting in ways that can harm the kidneys over time. Here’s a closer look at each one:

IgA Nephropathy (IgAN)

A rare autoimmune condition where the immune system produces antibodies, which accumulate in the kidneys, that leads to kidney inflammation.

Lupus Nephritis (LN)

A rare autoimmune condition where the immune system attacks the body's own cells, affecting many organs, including the kidneys.

C3 Glomerulopathy (C3G)

A rare autoimmune condition in which C3, a protein your body creates for protection, abnormally deposits in the kidneys, leading to kidney damage and affecting the kidney’s ability to filter blood.

What Happens Over Time

If left untreated, IgAN, LN, or C3G, may progress to kidney failure, necessitating kidney replacement therapy and life-long treatments.  

To learn more about how ADX-097 may lessen kidney function loss, click "How Is The Study Drug Designed to Work?"
F Images

HOW IS THE STUDY DRUG DESIGNED TO WORK?

The study drug is called ADX-097 and remains experimental.  

It is designed to work by homing specifically to the inflamed tissue to inhibit the part of the immune system called the complement system.

Through a part of the molecule called factor H, it is designed to affect the part of the complement system called the alternative pathway (AP), which is important for amplifying the activation of the complement system. The complement system, and particularly the AP, is commonly overly activated in kidney diseases including Lupus Nephritis, IgA Nephropathy and C3 Glomerulopathy.  

ADX-097 aims to inhibit the complement system to reduce the activity of the AP which may lessen kidney damage and kidney function loss, while also reducing the risk of side effects of common kidney disease-related medications and the need for frequent, high-dose treatments.

Conditions We're Supporting

This clinical study focuses on understanding and treating three conditions that can lead to serious kidney disease. Each of these conditions involves the immune system acting in ways that can harm the kidneys over time. Here's a closer look at each one:

Can I Participate?

You may be able to participate in the SPOTLIGHT clinical study if you:

Feature Icon
Are 18 years or older.
Feature Icon
Have a confirmed diagnosis of IgAN, LN, or C3G.
If you do not have a formal IgAN, LN, or C3G diagnosis, you may be evaluated at the site. The study team can discuss this with you further.

What You May Receive

By enrolling in this study, you may receive:

Access to physicians with experience in managing IgAN, LN, or C3G.

Compensation for time and travel related to study visits.

The investigational study drug at no cost to you.

Feature Image

Why Join?

The SPOTLIGHT Study aims to reduce protein excretion in the urine and reduce kidney function loss, both of which may lead to the need for dialysis or kidney transplantation.

Your participation assists physicians to advance the medical knowledge of conditions like IgAN, LN, and C3G, and potentially improve treatments for patients like you.

What To Expect

If you're interested in learning more about this clinical study, here are a few steps you can expect to complete.

01

See If You May Qualify

Click here to see if you may qualify for the study. Then, select a date and time for a short phone call with a PatientWing representative.

Applying is voluntary and doesn’t require commitment to study participation.

02

Phone Call with PatientWing

If initially eligible, a PatientWing representative will call you to discuss the study, additional eligibility criteria, and answer your questions. You should also discuss the study with your doctor and family members.

If you are still eligible at the end of this screening call, you’ll be connected to a member of the team at a research site location.

03

Screening at the Research Site

The team at a participating research site will determine if you are eligible to participate in the study by reviewing your medical records.

In case you might need to do a kidney biopsy, the study team will discuss the procedure with you.

04

Study

Eligible patients will be in the study for approximately 42 weeks and will require 30 in-person visits to the research site.

Each visit will last between 30 minutes to 3 hours.

What To Expect

If you're interested in learning more about this clinical study, here are a few steps you can expect to complete.

Option Item Img

See If You May Qualify

Click here to see if you may qualify for the study. Then, select a date and time for a short phone call with a PatientWing representative.

Applying is voluntary and doesn’t require commitment to study participation.
Option Item Img

Phone Call with PatientWing

If initially eligible, a PatientWing representative will call you to discuss the study, additional eligibility criteria, and answer your questions. You should also discuss the study with your doctor and family members.

If you are still eligible at the end of this screening call, you’ll be connected to a member of the team at a research site location.
Option Item Img

Screening at the Research Site

The team at a participating research site will determine if you are eligible to participate in the study by reviewing your medical records.

In case you might need to do a kidney biopsy, the study team will discuss the procedure with you.
Option Item Img

Study

Eligible patients will be in the study for approximately 42 weeks and will require 30 in-person visits to the research site.
  • This includes the 26-week treatment period and a 4-week follow-up period.
  • Each visit will last between 30 minutes to 3 hours.

Frequently Asked Questions

How do I get started?
How does the study drug, ADX-097, work?
Is there a chance I will receive a placebo?
How long will the study take place?
I’m not sure I have IgAN, LN, or C3G. Can I still participate?
Will I receive compensation?

About The Study Team

Option Item Img
Q32 Bio is a biopharmaceutical company dedicated to transforming the lives of patients with immune disease through discovery and development of targeted biotherapeutics that rebalance the immune system.
Option Item Img
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare diseases and expertise in navigating the enrollment process, we're here for you every step of the way.

Stay Connected

Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities

By subscribing you consent to receive marketing communications from PatientWing

Check - Elements Webflow Library - BRIX Templates
Thanks for joining our newsletter
Oops! Something went wrong while submitting the form.
TOP
See If You May Qualify